Matthew K Fust Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

Matthew K Fust is Director of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 22,836 shares of CRNX, which is worth approximately $980,577. The most recent transaction as insider was on Sep 26, 2025, when has been sold 16,000 shares (Common Stock) at a price of $44.75 per share, resulting in proceeds of $716,000. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 22.8K

20.81% 3M change

4.1% 12M change

Total Value Held $980,577

Matthew K Fust Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 26 2025	SELL Open market or private sale	$716,000 $44.75 p/Share	16,000 Reduced 41.2%	22,836 Common Stock
Sep 26 2025	BUY Exercise of conversion of derivative security	$19,100 $1.91 p/Share	10,000 Added 20.48%	38,836 Common Stock
Jun 11 2025	BUY Grant, award, or other acquisition	-	6,900 Added 19.31%	28,836 Common Stock
Jun 07 2024	BUY Grant, award, or other acquisition	-	3,400 Added 13.42%	21,936 Common Stock
Mar 20 2024	SELL Open market or private sale	$2,643,600 $44.06 p/Share	60,000 Reduced 76.4%	18,536 Common Stock
Mar 20 2024	BUY Exercise of conversion of derivative security	$1,275,000 $21.25 p/Share	60,000 Added 62.48%	36,036 Common Stock
Jun 16 2023	BUY Grant, award, or other acquisition	-	6,000 Added 24.45%	18,536 Common Stock
Jul 13 2022	SELL Open market or private sale	$119,472 $20.96 p/Share	5,700 Reduced 31.26%	12,536 Common Stock
Jul 13 2022	BUY Exercise of conversion of derivative security	$8,265 $1.45 p/Share	5,700 Added 23.81%	18,236 Common Stock
Nov 01 2021	SELL Open market or private sale	$228,327 $25.5 p/Share	8,954 Reduced 41.67%	12,536 Common Stock
Nov 01 2021	BUY Exercise of conversion of derivative security	$17,102 $1.91 p/Share	8,954 Added 29.41%	21,490 Common Stock
Sep 08 2021	SELL Open market or private sale	$154,173 $25.5 p/Share	6,046 Reduced 32.54%	12,536 Common Stock
Sep 08 2021	BUY Exercise of conversion of derivative security	$11,548 $1.91 p/Share	6,046 Added 24.55%	18,582 Common Stock
Jul 26 2021	SELL Open market or private sale	$97,950 $19.59 p/Share	5,000 Reduced 28.51%	12,536 Common Stock
Jul 26 2021	BUY Exercise of conversion of derivative security	$9,550 $1.91 p/Share	5,000 Added 22.19%	17,536 Common Stock
Jul 19 2021	SELL Open market or private sale	$97,500 $19.5 p/Share	5,000 Reduced 28.51%	12,536 Common Stock
Jul 19 2021	BUY Exercise of conversion of derivative security	$9,550 $1.91 p/Share	5,000 Added 22.19%	17,536 Common Stock
Jul 12 2021	SELL Open market or private sale	$103,550 $20.71 p/Share	5,000 Reduced 28.51%	12,536 Common Stock
Jul 12 2021	BUY Exercise of conversion of derivative security	$9,550 $1.91 p/Share	5,000 Added 22.19%	17,536 Common Stock
Dec 16 2019	SELL Open market or private sale	$78,750 $22.5 p/Share	3,500 Reduced 21.83%	12,536 Common Stock
Dec 16 2019	BUY Exercise of conversion of derivative security	$6,685 $1.91 p/Share	3,500 Added 17.92%	16,036 Common Stock

Also insider at

ATRA

Atara Biotherapeutics, Inc. Healthcare

RARE

Ultragenyx Pharmaceutical Inc. Healthcare

NMRA

Neumora Therapeutics, Inc.

MKF

Matthew K Fust

Director

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Value

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Track Activities on CRNX

Account